Embed Size (px)
Citation preview
« Issuing the right anti-cancer treatment atthe time, each and every time »
« Precision Oncology Molecular Tests enabling Personalized Anti-Cancer Treatments »
Linkedin.com/in/b-mat-ilab-573107167
@BMATILAB
+39 340 8894902
www.bmatilab.com
« New aimed therapies, given the numerous different tumor types with extremelydifferent genetic backgrounds, will probably work in only 2-16% of patients »
Genomic guidedTargeted Therapy
ResponseRate
Targeted Therapywithout genomic profile
> 85%
2-16%
« There are over 700 targeted anti-cancer drugs which have been either approved orundergoing clinical trial. There are hundreds of different tumor types all having differentgenetic mutations all responding differently to these therapies »
« Using validated genomic and proteomic research tests response rate to the newgeneration of targeted drugs can increase reaching up to 85% »
« Remove uncertainty regarding treatment decision: Target the Cancer with the correct Targeted Therapy »
BMAT-ILAB SERVICES
Genomic and Proteomic Research Tests
- Cancer Tissue DNA Genomic Profile
- Cancer Tissue Proteomic ProfileDNA extraction or proteomic study
from routine hystology biopsy sample
- Blood ctDNA* Genomic ProfileDNA extraction from routine blood test(liquid biopsy)
« DNA analysis identifies cancer driving mutations, translocations and rearrangements generating apersonalize genetic profile »
« The detected genomic profile is matched to the most appropriate anti-cancer drug which havebeen designed to specifically target these particular abnormalities therefore increasing patients
chances of successful treatment »
* ctDNA: circulating tumor DNA
BMAT-ILAB SERVICES
Genomic and Proteomic Research Tests
- Blood CTC* AnalysisCTC isolation from blood test,pathological study and/or genomic profile
« Could identify precisely nature of cancers of unknow origin throught CTC pathological study andsequencing CTC DNA »
« BMAT-ILAB offers medical support expecially in cases of rare cancer or of unknow origin withinternational expert oncologist respecting FDA/EMA approvals and NCCN/ESMO guidelines »
* CTC: circulating tumor cells ; FDA: food & drugs administration ; EMA: european medicines agency ; NCCN: national comprehensive cancer network ;ESMO: european society for medical oncology
« Remove uncertainty regarding treatment decision: Target the Cancer with the correct Targeted Therapy »
BMAT-ILAB SERVICES
Genomic and Proteomic Research Tests
- Patients with early cancer
- Identifying optimal treatment option following initial diagnosis to achieve maximumbenefit
- Identifying precisely the right anti-cancer drug and avoiding side effects and cost of drugsunlikely to be of benefit
- Patients with widespread advanced cancers who have exhausted conventional approaches- Patients with rare cancer and limited options- Patients with cancer of unknown origin or not otherwise diagnosable
- Molecular tests can identify a wide range of additional therapeutic options or offerelements for diagnosis
Which patients will benefit?
BMAT-ILAB SERVICES
Genomic and Proteomic Research Tests
Examples of Use in Clinical Practice
Genomic and ProteomicTests identify tumortype with the righttarget therapy
B-RAF mutation
Vemurafenib
EGFR mutation
Afatinib
KIT mutation
IMATINIB
ROS1mutation
Crizotinib
PIK3CAamplification
CLR-457
Monitor the cancer during targetedtreatments to identify new genetic changesor early onset resistances
Cancer cells escape from therapeutic effectof anti-cancer drug
BMAT-ILAB SERVICES
Genomic and Proteomic Research Tests
How to obtain BMAT-ILAB services?
« Contact our specialists by mail ([email protected]) or complete request form fromour website (www.bmatilab.com)
« Send a copy of the pathology report with the routine histology biopsy sample (paraffintissue blocks) or blood samples (4 ml Tubes with liquid EDTA labelled) to be testedthrought international courier service at:
BMAT-ILAB, Studio Soda, Via Aquileia 15, 00198, Rome, Italy
« On receiving the sample tests will be carried out with a clinical report within 15-21working days
« BMAT-ILAB research tests link the majorityof targeted anti-cancer drugs availableincluding FDA and EMA approved drugs orthose carrying NCCN and ESMO guidelinereferences to virtually all cancer types »
Linkedin.com/in/b-mat-ilab-573107167
@BMATILAB
+39 340 8894902
www.bmatilab.com
![Manuallymphaticdrainageforlymphedemafollowingbreast cancertreatment… · 2019. 1. 8. · [Intervention Review] Manual lymphatic drainage for lymphedema following breast cancer treatment](https://img.dokumen.tips/doc/110x75/6122b14d4796fe601d43a8c0/manuallymphaticdrainageforlymphedemafollowingbreast-cancertreatment-2019-1-8.jpg)
![Improving Access to Standardized Fertility Preservation ... · fertility preservation procedures [15]. This is unfortunate be-cause in light of cancertype, cancertreatment,and prognosis,](https://img.dokumen.tips/doc/110x75/5f04a9f47e708231d40f171b/improving-access-to-standardized-fertility-preservation-fertility-preservation.jpg)
